Biomarker Technologies Market to Reach USD 140.38 Billion by 2029 as Precision Medicine and Advanced Diagnostics Accelerate Adoption

Biomarker Technologies Market Overview

The global Biomarker Technologies Market was valued at USD 74.37 billion in 2022 and is expected to reach USD 140.38 billion by 2029, growing at a CAGR of 9.5% during the forecast period 2023–2029, according to Maximize Market Research. Biomarker technologies enable the identification and measurement of biological characteristics associated with disease conditions, treatment response and physiological processes. Their growing use in disease diagnosis, drug development, risk assessment and personalized medicine is strengthening demand across the healthcare and life sciences sectors.

The increasing incidence of cancer, diabetes, cardiovascular diseases and neurological disorders is a major factor supporting market expansion. Biomarkers enable earlier disease detection and can improve patient stratification, treatment selection and monitoring. Rising healthcare expenditure, growing adoption of personalized medicine, government support for biomarker development and increasing R&D investment by biotechnology companies and research institutions are creating additional opportunities. At the same time, high capital requirements associated with biomarker discovery and development remain a key challenge. The expansion of liquid biopsy, next-generation sequencing, immunoassays, multiomics and data-driven diagnostics is expected to create substantial opportunities for technology providers.

* Request a Free Sneak Peek: https://www.maximizemarketresearch.com/request-sample/31714/ 

U.S. Market Trends and Investment

The United States continues to be a major center for biomarker research, supported by government-funded research programs and increasing pharmaceutical and biotechnology investment in precision medicine. In 2025, the National Institutes of Health continued to support biomarker development and validation through dedicated funding opportunities. The National Cancer Institute's 2025 program supports analytical and clinical validation of molecular, cellular and imaging markers for cancer detection, diagnosis, prognosis, treatment-response prediction and prevention. NINDS also maintained funding programs focused on developing and validating biomarkers for neurological and neuromuscular disorders. In addition, an NIH-funded Mayo Clinic project received USD 9.16 million in FY2025 to advance blood-based molecular signatures for Alzheimer's disease. These initiatives demonstrate continued U.S. investment in translating biomarker discoveries into clinically useful precision-medicine tools.

Market Segmentation

According to the supplied MMR report, the Biomarker Technologies Market is segmented by Test Type, Technology, Product, Research and Application. Test types include Solid Biopsy and Liquid Biopsy. Technologies include ddPCR, NGS, Immunoassay, Mass Spectrometry, DHPLC and other technologies. Products comprise Consumables, Instruments, Services and Software/Informatics, while research areas include Genomics, Proteomics, Metabolomics, Metabolic Flux, Lipidomics and others. Applications include Drug Discovery, Diagnostics and Personalized Medicine.

By Product Type, the Consumables segment held the largest market share in 2022 and is expected to maintain its dominance throughout the forecast period. MMR attributes this leadership to the critical role consumables play in biomarker testing, with reagents and kits accounting for the largest share within the consumables category. By Profiling Technology, Immunoassay held the largest share in 2022, supported by the broad use of ELISA and related techniques for protein biomarker quantification and validation.

Biomarker Technologies Market Key Players:
1. Thermo Fisher Scientific
2. Bio-Rad Laboratories
3. Danaher Corporation
4. Agilent Technologies
5. Roche
6. Waters Corporation
7. Shimadzu Corporation
8. Illumina, Inc.
9. F. Hoffmann-La Roche AG
10. Merck KGAA
11. PerkinElmer Inc.
12. Siemens Healthcare
13. Abbott Laboratories
14. Qiagen N.V.
15. Biomérieux SA,
16. Becton,
17. Myriad Genetics,
18. Sysmex Corporation,
19. Quest Diagnostics
20. Aushon BioSystem Inc.,
21. Epistem Ltd.
22. Hologic

Competitive Analysis

The MMR report identifies Thermo Fisher Scientific, Bio-Rad Laboratories, Danaher Corporation, Agilent Technologies, Roche, Waters Corporation, Shimadzu Corporation, Illumina, Inc., F. Hoffmann-La Roche AG, Merck KGaA, PerkinElmer, Siemens Healthcare, Abbott Laboratories, Qiagen, bioMérieux, Becton, Myriad Genetics, Sysmex Corporation, Quest Diagnostics, Aushon BioSystem, Epistem and Hologic as key market participants. The MMR page does not provide verified individual market-share percentages; therefore, exact top-five share rankings are not fabricated.

Thermo Fisher Scientific strengthened the biomarker discovery ecosystem in 2025 when its Olink platform was selected for the UK Biobank Pharma Proteomics Project. The project aims to analyze more than 5,400 proteins across 600,000 samples, creating a large-scale resource for identifying disease-associated protein biomarkers.

Illumina significantly expanded its biomarker and multiomics capabilities in 2025. The company launched an enhanced TruSight Oncology 500 assay with built-in homologous recombination deficiency biomarker detection and introduced DRAGEN v4.4 with improved structural-variant calling and oncology applications. It also launched SomaSeq Discovery, capable of measuring 9,500 human protein targets, strengthening large-scale proteomic biomarker discovery.

Roche advanced companion diagnostics and blood-based biomarker testing in 2025. The FDA approved its VENTANA MET SP44 RxDx Assay for identifying MET protein expression in certain lung cancer patients, while Roche also received CE Mark for its Elecsys pTau181 blood test for ruling out Alzheimer's-associated amyloid pathology.

Agilent Technologies continued expanding its life-sciences infrastructure, opening a new Biopharma Experience Center in Hyderabad in July 2025 to support biopharmaceutical research and innovation.

Danaher Corporation remains an important participant identified by MMR, with its broad diagnostics, life-science tools and biotechnology portfolio supporting biomarker research, laboratory testing and precision-health applications.

Regional Analysis

North America held the largest share of the global Biomarker Technologies Market in 2022, according to MMR. The region's leadership is supported by the increasing prevalence of cancer, autoimmune diseases, cardiovascular disorders and neurological diseases, alongside high healthcare expenditure and an aging population. Strong research infrastructure, government-funded programs and the presence of major biomarker technology companies further strengthen the regional market.

Within North America, the United States represents a particularly important market because of its advanced healthcare infrastructure and substantial public and private investment in biomarker discovery and validation. NIH programs supporting cancer, neurological and digital biomarkers are helping move technologies from research environments toward clinical applications.

Related Reports

Global Viral Clearance Market https://www.maximizemarketresearch.com/market-report/global-viral-clearance-market/17220/ 

Global Secondary Macronutrients Market https://www.maximizemarketresearch.com/market-report/global-secondary-macronutrients-market/66152/ 

Cell Culture Market https://www.maximizemarketresearch.com/market-report/global-cell-culture-market/33004/ 

Conclusion

The Biomarker Technologies Market is positioned for sustained growth as healthcare systems increasingly move toward early diagnosis, precision medicine and targeted treatment. The projected expansion from USD 74.37 billion in 2022 to USD 140.38 billion by 2029 highlights the growing commercial and clinical importance of biomarker technologies.

In our view, the strongest opportunities will come from liquid biopsy, multiomics, proteomics, NGS-based biomarker discovery, companion diagnostics and AI-enabled analysis. Greater investment in clinical validation and standardized testing will be essential for converting promising biomarkers into routine diagnostic and therapeutic tools. Continued government funding, pharmaceutical R&D and advances in high-throughput technologies are expected to remain major catalysts for market growth.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com